CD37 and B-cell non-Hodgkin lymphoma: CD37, whose expression correlates with favorable prognosis, can protect against the development of B cell lymphoma by interacting with the suppressor of cytokine signaling 3 (SOCS3) to inhibit IL-6 signaling [15, 85].